EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A



Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A



Haematologica 103(1): 179-189



Around one third of boys with severe hemophilia A develop inhibitors (neutralizing antibodies) against their therapeutic factor VIII product. This adverse effect may result in more life-threatening bleeding, disability, impaired quality of life, and costly care. We compared the incidence of inhibitors in boys treated with the three factor VIII products most used in France: one plasma-derived (Factane) and two recombinant products (Advate and Kogenate Bayer). A previously untreated cohort of patients was created in 1994 to investigate risk factors for inhibitor development. We selected boys with severe hemophilia A (factor VIII <1 IU/dL) first treated with one of the three factor VIII products studied. Details of product infusions, inhibitor assays and main fixed and time-varying inhibitor risk factors were recorded for the first 75 exposure days. Three outcomes (all inhibitors, high-titer inhibitors and subsequently treated inhibitors) were analyzed by univariate and multivariate Cox models. We studied 395 boys first treated between 2001 and 2016 (131, 137, and 127 with Factane, Advate, and Kogenate Bayer, respectively). Clinically significant inhibitors were diagnosed in 121 patients (70 high-titer). The incidence of high-titer inhibitors was significantly associated with the factor VIII product received (P=0.005): the cumulative incidence at 75 exposure days was 12.7% (95% CI: 7.7-20.6) with Factane, 20.4% (95% CI: 14.0-29.1) with Advate, and 31.6% (95% CI: 23.5-41.7) with Kogenate Bayer. The low inhibitor incidence observed with Factane is concordant with recent findings from the SIPPET randomized trial. These consistent results from observational and experimental studies should lead to improved care for previously untreated patients and cost savings for healthcare systems worldwide.

(PDF emailed within 0-6 h: $19.90)

Accession: 059352689

Download citation: RISBibTeXText

PMID: 29025913

DOI: 10.3324/haematol.2017.174706



Related references

Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 109(11): 4693-4697, 2007

Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States. Journal of Medical Economics 21(8): 762-769, 2018

Reflections on the FranceCoag report on inhibitory antibodies to factor VIII in patients with severe hemophilia A. Blood 125(24): 3816-3817, 2015

Multicenter comparison of inhibitor development on plasma-derived vs recombinant factor VIII in severe hemophilia A patients. Blood 94(10 SUPPL 1 PART 1): 238a, Nov 15, 1999

Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A. Blood 124(23): 3398-3408, 2015

Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review. Critical Reviews in Oncology/Hematology 81(1): 82-93, 2012

Plasma-derived versus recombinant factor VIII for the treatment of hemophilia A. Vox Sanguinis 70(SUPPL 3): 17-20, 1996

Comparative immunogenicity of recombinant B domain-deleted porcine factor VIII and Hyate:C in hemophilia A mice presensitized to human factor VIII. Journal of Thrombosis and Haemostasis 2(4): 605-611, 2004

Biological considerations of plasma-derived and recombinant factor VIII immunogenicity. Blood 129(24): 3147-3154, 2017

Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group. New England Journal of Medicine 323(26): 1800-1805, 1990

Rates of Inhibitor development in previously untreated patients with severe hemophilia A treated with plasma-derived or recombinant factor VIII: no proof of difference or proof of no difference?. Seminars in Thrombosis and Hemostasis 40(2): 269-270, 2014

Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice. Blood 114(4): 871-880, 2009

Pharmacokinetics of recombinant and plasma-derived factor IX products in pediatric patients with severe hemophilia B. Blood Coagulation & Fibrinolysis 26(1): 113-114, 2015

Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice. Journal of Pharmaceutical Sciences 95(2): 358-371, 2005

Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. Journal of Thrombosis and Haemostasis 8(6): 1256-1265, 2010